The Experts below are selected from a list of 51 Experts worldwide ranked by ideXlab platform
Jerome H. Check - One of the best experts on this subject based on the ideXlab platform.
-
Sympathomimetic Amines effectively control pain for interstitial cystitis that had not responded to other therapies.
Clinical and experimental obstetrics & gynecology, 2013Co-Authors: Jerome H. Check, Cohen G, Rachael Cohen, Dipietro J, Steinberg BAbstract:PURPOSE To further investigate the efficacy of treatment of interstitial cystitis that had been refractory to standard treatment with Sympathomimetic Amines. METHODS Dextroamphetamine sulfate sustained release capsules up to 30 mg per day were prescribed in women with refractory painful bladder syndrome/interstitial cystitis in six new cases. The patients were carefully evaluated for relief of symptoms. RESULTS All six women found marked relief in their painful bladder syndrome in a rather short length of time. The benefit persisted as long as the therapy was maintained. Temporary cessation resulted in prompt return of symptoms, but resumption of Sympathomimetic Amines again allowed good relief of bladder pain and related symptoms. CONCLUSIONS Because of very few side-effects and no drug dependence in the dosage used, Sympathomimetic Amines should be considered for first-line therapy.
-
Marked improvement of headaches and vasomotor symptoms with Sympathomimetic Amines in a woman with sympathetic hyperalgesia-edema syndrome.
Clinical and experimental obstetrics & gynecology, 2011Co-Authors: Jerome H. Check, Cohen RAbstract:PURPOSE To determine if relief from various pain conditions with Sympathomimetic Amines may be a direct effect on pain fibers or related to improvement of edema. METHODS A woman with severe migraine headaches resistant to standard therapy was treated with dextroamphetamine sulfate. RESULTS The headaches markedly improved shortly after treatment as did her vasomotor symptoms. However, in this case the inability to lose weight despite dieting related to edema did not improve. CONCLUSIONS The improvement of pain and vasomotor symptoms in this disorder of the sympathetic nervous system does not seem to necessarily be related to edema causing pain. Sympathomimetic Amines may have a direct effect on sympathetic nervous system fibers. Thus, a more appropriate term for this condition instead of idiopathic orthostatic cyclic edema would be sympathetic hyperalgesia-edema syndrome.
-
Successful treatment of a female with chronic pseudo-intestinal obstruction with Sympathomimetic Amines and thyroid hormone replacement.
Clinical and experimental obstetrics & gynecology, 2010Co-Authors: Jerome H. Check, R CohenAbstract:Purpose To determine if a defect in Sympathomimetic Amines, which is a common cause of various undiagnosed pain syndromes in women could be the cause of chronic pseudointestinal obstruction. Furthermore to determine if this life-threatening illness may similarly respond to Sympathomimetic Amines as in other pain syndromes, e.g., pelvic pain and interstitial cystitis. Method A 23-year-old, five foot, female with chronic pseudointestinal obstruction, who lost 35 pounds down to 75 pounds, was treated with 15 mg dextroamphetamine sulfate and 50 microg of L-thyroxin (her TSH thyroid hormone level was markedly suppressed in the face of a slightly low free thyroxin level. Results Her abdominal pain lessened then completely disappeared within a few weeks. Within one year she gained 25 pounds. Conclusions Chronic pseudointestinal obstruction is another way idiopathic orthostatic edema (a condition found predominantly in women) may manifest. Similar to other gastrointestinal pain syndromes and pain in other areas, e.g., pelvis, bladder, head and joints, treatment with Sympathomimetic Amines results in dramatic improvement.
-
Dramatic relief of chronic pelvic pain with treatment with Sympathomimetic Amines--case report.
Clinical and experimental obstetrics & gynecology, 2007Co-Authors: Jerome H. Check, C WilsonAbstract:Purpose To describe a novel treatment of chronic pelvic pain. Methods Dextroamphetamine sulfate was prescribed to a woman with unexplained chronic pelvic pain. Pelvic ultrasound, colonoscopy, and lower gastrointestinal radiographic studies were negative. Laparoscopy was offered as the next diagnostic test but the woman requested an attempt at medical therapy first. Based on previous experience of dramatic relief of chronic pelvic pain of bladder origin with Sympathomimetic amine therapy she was started on dextroamphetamine sulfate. Results The relief of pain approximated 100% almost immediately and the pain relief has persisted for six months. Inadvertent failure to take the prescribed medication allowed the pain to return immediately only to disappear again once the medication was taken. Conclusions Disorders of the Sympathomimetic nervous system may be a cause of chronic pelvic pain and are relieved by treatment with Sympathomimetic Amines.
-
Sympathomimetic Amines as a novel treatment for refractory chronic idiopathic urticaria
Journal of Allergy and Clinical Immunology, 2004Co-Authors: Jerome H. Check, C. Amadi, H. KaplanAbstract:Abstract Rationale To corroborate or refute a previous case report showing marked improvement in severe chronic idiopathic urticaria (CIU) by the use of Sympathomimetic Amines. Methods Retrospective review of all patients who were refractory to conventional medication such as various anti-histAmines and corticosteroids that were treated with dextroamphetamine sulfate spansules 20-30mg/day. The patients were evaluated for degree and persistence of improvement. Results Four reviewed cases with chronic idiopathic urticaria of a mean 9 years duration (range 4-17 years) showed either moderate to significant improvement following dextroamphetamine sulfate therapy. One patient also had angioedema which also improved considerably following therapy. No cases had to stop using dextroamphetamine sulfate because of side effects. All cases remain improved for treatment duration of 4 years minimum and a maximum of 8 years. Conclusions These data corroborate previous findings of 2 previous reported cases that Sympathomimetic Amines can effectively control chronic idiopathic urticaria that was refractory to conventional therapy. Furthermore, these additional 4 cases show that the effectiveness of therapy does not wane over time. The duration of effectiveness was not evaluated in the 2 previous cases. Also, the therapy was well tolerated. Thus, to date, in a small series of 6 cases, Sympathomimetic amine treatment caused significant improvement in 100% of studied cases. A search of the English literature failed to find any publications pro or con about this therapy for CIU in the 20 years since the original publications. Hopefully these data will prompt interest in performing a larger prospective study.
T Martin - One of the best experts on this subject based on the ideXlab platform.
-
distinguishing Sympathomimetic Amines from amphetamine and methamphetamine in urine by gas chromatography mass spectrometry
Journal of Analytical Toxicology, 1992Co-Authors: E M Thurman, M J Pedersen, R L Stout, T MartinAbstract:Derivatives of seven commonly used Sympathomimetic Amines and two "designer Amines" were isolated from urine, separated chromatographically from amphetamine and methamphetamine, and determined by mass spectrometry with selected ion monitoring. The drugs included ephedrine, propylhexedrine, pseudoephedrine, phenylpropanolamine, hydroxynorephedrine, phenylephrine, phentermine, methylenedioxyamphetamine (MDA), and methylenedioxy methamphetamine (MDMA). The drugs were liquid extracted from urine and derivatized by either heptafluorobutyric anhydride (HFBA) or 4-carbethoxyhexafluorobutyryl chloride (4-CB). Because the base peak ions for ephedrine, pseudoephedrine, propylhexedrine, MDMA, and phentermine are identical to methamphetamine (e.g. 254 amu for HFBA) and those for phenylephrine, hydroxynorephedrine, phenylpropanolamine, and MDA are identical to amphetamine (e.g. 240 amu for HFBA), a table of selected ions was developed for all 11 drugs that distinguished amphetamine and methamphetamine from the Sympathomimetic Amines with either HFBA or 4-CB. The distinguishing ions rely on the ring structure of the different drugs and fragmentation associated with that structure. The 4-CB reagent partially derivatized the hydroxy-containing Sympathomimetic Amines, while the HFBA completely derivatized all the Sympathomimetic Amines. Furthermore, false positive results for the 4-CB reagent were found only for methamphetamine (20-2250 ng/mL of methamphetamine) when high concentrations (greater than 5 micrograms) of ephedrine or pseudoephedrine were present in the specimen. These results are related to a combination of injection port temperature and cleanliness of the injection port sleeve.
-
Distinguishing Sympathomimetic Amines from amphetamine and methamphetamine in urine by gas chromatography/mass spectrometry
Journal of analytical toxicology, 1992Co-Authors: E M Thurman, M J Pedersen, R L Stout, T MartinAbstract:Derivatives of seven commonly used Sympathomimetic Amines and two "designer Amines" were isolated from urine, separated chromatographically from amphetamine and methamphetamine, and determined by mass spectrometry with selected ion monitoring. The drugs included ephedrine, propylhexedrine, pseudoephedrine, phenylpropanolamine, hydroxynorephedrine, phenylephrine, phentermine, methylenedioxyamphetamine (MDA), and methylenedioxy methamphetamine (MDMA). The drugs were liquid extracted from urine and derivatized by either heptafluorobutyric anhydride (HFBA) or 4-carbethoxyhexafluorobutyryl chloride (4-CB). Because the base peak ions for ephedrine, pseudoephedrine, propylhexedrine, MDMA, and phentermine are identical to methamphetamine (e.g. 254 amu for HFBA) and those for phenylephrine, hydroxynorephedrine, phenylpropanolamine, and MDA are identical to amphetamine (e.g. 240 amu for HFBA), a table of selected ions was developed for all 11 drugs that distinguished amphetamine and methamphetamine from the Sympathomimetic Amines with either HFBA or 4-CB. The distinguishing ions rely on the ring structure of the different drugs and fragmentation associated with that structure. The 4-CB reagent partially derivatized the hydroxy-containing Sympathomimetic Amines, while the HFBA completely derivatized all the Sympathomimetic Amines. Furthermore, false positive results for the 4-CB reagent were found only for methamphetamine (20-2250 ng/mL of methamphetamine) when high concentrations (greater than 5 micrograms) of ephedrine or pseudoephedrine were present in the specimen. These results are related to a combination of injection port temperature and cleanliness of the injection port sleeve.
H. Kaplan - One of the best experts on this subject based on the ideXlab platform.
-
Sympathomimetic Amines as a novel treatment for refractory chronic idiopathic urticaria
Journal of Allergy and Clinical Immunology, 2004Co-Authors: Jerome H. Check, C. Amadi, H. KaplanAbstract:Abstract Rationale To corroborate or refute a previous case report showing marked improvement in severe chronic idiopathic urticaria (CIU) by the use of Sympathomimetic Amines. Methods Retrospective review of all patients who were refractory to conventional medication such as various anti-histAmines and corticosteroids that were treated with dextroamphetamine sulfate spansules 20-30mg/day. The patients were evaluated for degree and persistence of improvement. Results Four reviewed cases with chronic idiopathic urticaria of a mean 9 years duration (range 4-17 years) showed either moderate to significant improvement following dextroamphetamine sulfate therapy. One patient also had angioedema which also improved considerably following therapy. No cases had to stop using dextroamphetamine sulfate because of side effects. All cases remain improved for treatment duration of 4 years minimum and a maximum of 8 years. Conclusions These data corroborate previous findings of 2 previous reported cases that Sympathomimetic Amines can effectively control chronic idiopathic urticaria that was refractory to conventional therapy. Furthermore, these additional 4 cases show that the effectiveness of therapy does not wane over time. The duration of effectiveness was not evaluated in the 2 previous cases. Also, the therapy was well tolerated. Thus, to date, in a small series of 6 cases, Sympathomimetic amine treatment caused significant improvement in 100% of studied cases. A search of the English literature failed to find any publications pro or con about this therapy for CIU in the 20 years since the original publications. Hopefully these data will prompt interest in performing a larger prospective study.
Maryam Fazel - One of the best experts on this subject based on the ideXlab platform.
-
question based self reported experience of patients with subcutaneous adipose tissue sat disease prescribed Sympathomimetic Amines
Medical research archives, 2019Co-Authors: Karen L Herbst, Laila Abuzaid, Maryam FazelAbstract:Objective: Women with lipedema have painful excess subcutaneous fat on the limbs sparing the trunk. The fat in lipedema has fibrosis making it resistant to loss by diet and exercise (persistent fat). People with Dercum disease (DD) have painful masses in their fat tissue on the trunk and limbs. Lipedema can be confused with DD. Sympathomimetic Amines such as amphetamine, dextroamphetamine or phentermine anecdotally appear to improve weight loss and quality of life in people with lipedema or DD. The primary objective was to address perceived benefits and downsides of prescribed Sympathomimetic Amines (SA) including dextroamphetamine, amphetamine or phentermine in women with lipedema and men and women with DD. Methods: Fifty-four participants with lipedema and 26 with DD prescribed SA for ³3 months were consented to respond to a set of 82 categorical scale and descriptive questions and the validated lower extremity functional scale, based on the clinical experience of one of the authors (XXX) and her patients. Significance was set at a<0.05. Data were analyzed by Wilcoxon signed rank tests; continuous data was assessed by t-tests. Results: Participants with lipedema and DD prescribed SA perceived significant improvements in energy level, ability to exercise, leg heaviness, body pain, functionality, and memory. Average self-reported weight decreased by ~25 kg in participants with DD and ~12 kglothing size About 90% of participants felt their quality of life improved. Less than 20% of participants reported side effects from the Sympathomimetic Amines including insomnia, abdominal pain and visual changes. Conclusions: People with lipedema and DD report a significant benefit to risk ratio for their fat, pain and quality of life when prescribed Sympathomimetic Amines. A randomized prospective study would confirm benefits, safety and side effects.
-
Question-based Self-reported Experience of Patients with Subcutaneous Adipose Tissue (SAT) Disease Prescribed Sympathomimetic Amines
Medical research archives, 2019Co-Authors: Karen L Herbst, Laila Abu-zaid, Maryam FazelAbstract:Objective: Women with lipedema have painful excess subcutaneous fat on the limbs sparing the trunk. The fat in lipedema has fibrosis making it resistant to loss by diet and exercise (persistent fat). People with Dercum disease (DD) have painful masses in their fat tissue on the trunk and limbs. Lipedema can be confused with DD. Sympathomimetic Amines such as amphetamine, dextroamphetamine or phentermine anecdotally appear to improve weight loss and quality of life in people with lipedema or DD. The primary objective was to address perceived benefits and downsides of prescribed Sympathomimetic Amines (SA) including dextroamphetamine, amphetamine or phentermine in women with lipedema and men and women with DD. Methods: Fifty-four participants with lipedema and 26 with DD prescribed SA for ³3 months were consented to respond to a set of 82 categorical scale and descriptive questions and the validated lower extremity functional scale, based on the clinical experience of one of the authors (XXX) and her patients. Significance was set at a
E M Thurman - One of the best experts on this subject based on the ideXlab platform.
-
distinguishing Sympathomimetic Amines from amphetamine and methamphetamine in urine by gas chromatography mass spectrometry
Journal of Analytical Toxicology, 1992Co-Authors: E M Thurman, M J Pedersen, R L Stout, T MartinAbstract:Derivatives of seven commonly used Sympathomimetic Amines and two "designer Amines" were isolated from urine, separated chromatographically from amphetamine and methamphetamine, and determined by mass spectrometry with selected ion monitoring. The drugs included ephedrine, propylhexedrine, pseudoephedrine, phenylpropanolamine, hydroxynorephedrine, phenylephrine, phentermine, methylenedioxyamphetamine (MDA), and methylenedioxy methamphetamine (MDMA). The drugs were liquid extracted from urine and derivatized by either heptafluorobutyric anhydride (HFBA) or 4-carbethoxyhexafluorobutyryl chloride (4-CB). Because the base peak ions for ephedrine, pseudoephedrine, propylhexedrine, MDMA, and phentermine are identical to methamphetamine (e.g. 254 amu for HFBA) and those for phenylephrine, hydroxynorephedrine, phenylpropanolamine, and MDA are identical to amphetamine (e.g. 240 amu for HFBA), a table of selected ions was developed for all 11 drugs that distinguished amphetamine and methamphetamine from the Sympathomimetic Amines with either HFBA or 4-CB. The distinguishing ions rely on the ring structure of the different drugs and fragmentation associated with that structure. The 4-CB reagent partially derivatized the hydroxy-containing Sympathomimetic Amines, while the HFBA completely derivatized all the Sympathomimetic Amines. Furthermore, false positive results for the 4-CB reagent were found only for methamphetamine (20-2250 ng/mL of methamphetamine) when high concentrations (greater than 5 micrograms) of ephedrine or pseudoephedrine were present in the specimen. These results are related to a combination of injection port temperature and cleanliness of the injection port sleeve.
-
Distinguishing Sympathomimetic Amines from amphetamine and methamphetamine in urine by gas chromatography/mass spectrometry
Journal of analytical toxicology, 1992Co-Authors: E M Thurman, M J Pedersen, R L Stout, T MartinAbstract:Derivatives of seven commonly used Sympathomimetic Amines and two "designer Amines" were isolated from urine, separated chromatographically from amphetamine and methamphetamine, and determined by mass spectrometry with selected ion monitoring. The drugs included ephedrine, propylhexedrine, pseudoephedrine, phenylpropanolamine, hydroxynorephedrine, phenylephrine, phentermine, methylenedioxyamphetamine (MDA), and methylenedioxy methamphetamine (MDMA). The drugs were liquid extracted from urine and derivatized by either heptafluorobutyric anhydride (HFBA) or 4-carbethoxyhexafluorobutyryl chloride (4-CB). Because the base peak ions for ephedrine, pseudoephedrine, propylhexedrine, MDMA, and phentermine are identical to methamphetamine (e.g. 254 amu for HFBA) and those for phenylephrine, hydroxynorephedrine, phenylpropanolamine, and MDA are identical to amphetamine (e.g. 240 amu for HFBA), a table of selected ions was developed for all 11 drugs that distinguished amphetamine and methamphetamine from the Sympathomimetic Amines with either HFBA or 4-CB. The distinguishing ions rely on the ring structure of the different drugs and fragmentation associated with that structure. The 4-CB reagent partially derivatized the hydroxy-containing Sympathomimetic Amines, while the HFBA completely derivatized all the Sympathomimetic Amines. Furthermore, false positive results for the 4-CB reagent were found only for methamphetamine (20-2250 ng/mL of methamphetamine) when high concentrations (greater than 5 micrograms) of ephedrine or pseudoephedrine were present in the specimen. These results are related to a combination of injection port temperature and cleanliness of the injection port sleeve.
